ProMIS Neurosciences, Inc. (NASDAQ:PMN) Insider Neil Cashman Acquires 15,000 Shares

ProMIS Neurosciences, Inc. (NASDAQ:PMN) insider Neil Cashman purchased 15,000 shares of the stock in a transaction dated Monday, February 10th. The shares were purchased at an average cost of $0.97 per share, for a total transaction of $14,550.00. Following the completion of the acquisition, the insider now directly owns 16,617 shares in the company, valued at approximately $16,118.49. This trade represents a 927.64 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

ProMIS Neurosciences Price Performance

NASDAQ PMN opened at $0.91 on Thursday. The business’s fifty day moving average price is $0.94 and its 200-day moving average price is $1.08. The stock has a market capitalization of $29.85 million, a price-to-earnings ratio of -9.13 and a beta of 0.56. ProMIS Neurosciences, Inc. has a 1-year low of $0.87 and a 1-year high of $2.61.

Institutional Investors Weigh In On ProMIS Neurosciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Ally Bridge Group NY LLC increased its stake in shares of ProMIS Neurosciences by 50.3% in the 3rd quarter. Ally Bridge Group NY LLC now owns 1,592,605 shares of the company’s stock worth $1,991,000 after purchasing an additional 533,023 shares in the last quarter. Sphera Funds Management LTD. increased its stake in shares of ProMIS Neurosciences by 6.3% in the 3rd quarter. Sphera Funds Management LTD. now owns 1,929,297 shares of the company’s stock worth $2,412,000 after purchasing an additional 115,084 shares in the last quarter. Finally, Great Point Partners LLC purchased a new stake in shares of ProMIS Neurosciences in the 3rd quarter worth $3,488,000. 50.13% of the stock is currently owned by hedge funds and other institutional investors.

ProMIS Neurosciences Company Profile

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.